NVO - Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
2024-06-26 07:00:00 ET
Summary
- Novo Nordisk gains approval in China for blockbuster drug Wegovy.
- More than 11% of all adults in China live with diabetes - more than any other country in the world.
- Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-1 drugs, offering the potential for significant growth in the future.
- Eli Lilly is on track to become the first trillion-dollar company in the drug industry, with a market cap of $858 billion.
As obesity continues to become one of the biggest global health issues, weight loss drugs continue to reach new heights to meet the growing demand for quick weight loss solutions. Over the past year, I have written four articles on Eli Lilly and Company (LLY), with my most recent discussing its latest blockbuster drug Zepbound. I continue to believe that Lilly will become the first one-trillion-dollar company in the drug industry. Readers can review my original thesis in my February 8 article: Will Eli Lilly and Company Become A Trillion-Dollar Baby? ...
Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy